» Articles » PMID: 21091277

The ABCG2 Transporter and Its Relations with the Pharmacokinetics, Drug Interaction and Lipid-lowering Effects of Statins

Overview
Publisher Informa Healthcare
Date 2010 Nov 25
PMID 21091277
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Importance Of The Field: The ABCG2 efflux transporter is expressed in multiple tissues and plays an important role in the disposition of many statins. The functional 421C>A polymorphism in ABCG2 that reduces transporter activity has been found to be associated with increased systemic exposures to certain statins.

Areas Covered In This Review: We review and evaluate the associations of the ABCG2 polymorphism on the pharmacokinetics and clinical efficacy of statins.

What The Reader Will Gain: This article gives a detailed overview of the ABCG2 transporter and extensively reviews its relations with the pharmacokinetics and lipid-lowering effects of statins. This review also discusses the potential role of the ABCG2 polymorphism in the clinical outcomes in statin-treated patients and statin-drug interactions.

Take Home Message: The impact of the ABCG2 421C>A polymorphism on the disposition of the statins varies between different drugs and the effect on systemic exposure was greater in the case of rosuvastatin than other statins. This genetic variant was associated with greater low-density lipoprotein cholesterol response to rosuvastatin in Chinese and caucasian patients. The effect of the ABCG2 421C>A polymorphism on the lipid response to other substrate statins and clinical outcomes need to be evaluated in future studies.

Citing Articles

Effect of ABCG2 c.421 C> A (rs2231142) single nucleotide polymorphisms on the lipid-modulating efficacy of rosuvastatin: a meta-analysis.

Liu L, Deng Y, Li P, Zhang Z, Li H, Yang X BMC Cardiovasc Disord. 2025; 25(1):179.

PMID: 40082758 PMC: 11905716. DOI: 10.1186/s12872-025-04611-0.


Impacts of ABCG2 loss of function variant (p. Gln141Lys, c.421 C > A, rs2231142) on lipid levels and statin efficiency: a systematic review and meta-analysis.

Liu Y, Chen Y, Wei B, Li H, Peng Y, Luo Z BMC Cardiovasc Disord. 2024; 24(1):202.

PMID: 38589776 PMC: 11000409. DOI: 10.1186/s12872-024-03821-2.


Utilizing Pharmacogenomic Data for a Safer Use of Statins among the Emirati Population.

Alqasrawi M, Al-Mahayri Z, Alblooshi H, AlSafar H, Ali B Curr Vasc Pharmacol. 2024; 22(3):218-229.

PMID: 38284696 DOI: 10.2174/0115701611283841231227064343.


The frequency of rs2231142 in among Native Hawaiian and Pacific Islander subgroups: implications for personalized rosuvastatin dosing.

AlAzzeh O, Roman Y Pharmacogenomics. 2023; 24(3):173-182.

PMID: 36661065 PMC: 10072122. DOI: 10.2217/pgs-2022-0160.


The frequency of rs2231142 in  among Asian subgroups: implications for personalized rosuvastatin dosing.

Alrajeh K, Roman Y Pharmacogenomics. 2023; 24(1):15-26.

PMID: 36651271 PMC: 9979151. DOI: 10.2217/pgs-2022-0155.